We are analyzing https://link.springer.com/article/10.1186/1471-2407-12-306.

Title:
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients | BMC Cancer
Description:
Background Tumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also analyzed the prognostic value of the localization of CD163+ and CD68+ myeloid cells in human breast cancer. Methods The extent of infiltrating CD163+ or CD68+ myeloid cells in tumor nest versus tumor stroma was evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s Rho and χ2 tests were used to examine the correlations between CD163+ or CD68+ myeloid cells and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the impact of CD163+ and CD68+ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free survival, breast cancer specific and overall survival. Results We found that infiltration of CD163+ and CD68+ macrophages into tumor stroma, but not into tumor nest, were of clinical relevance. CD163+ macrophages in tumor stroma positively correlated with higher grade, larger tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like breast cancer and inversely correlated with luminal A breast cancer. Some CD163+ areas lacked CD68 expression, suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact. CD68+ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast cancer specific survival. Conclusion These findings highlight the importance of analyzing the localization rather than merely the presence of TAMs as a prognostic marker for breast cancer patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, breast, macrophages, cells, tumor, infiltration, pubmed, article, expression, google, scholar, patients, correlated, marker, tams, cas, prognostic, dense, luminal, figure, macrophage, survival, triplenegativebasallike, data, gene, table, analysis, stroma, size, receptor, density, myeloid, human, rfs, bcss, authors, presence, specific, outcome, correlation, patient, primary, file, clinical, subtypes, features, full, cell, antiinflammatory, localization,

Topics {✒️}

pre-publication history anti-granulin antibody hpa028747 specific monocyte/macrophage marker envisionflex high ph-kit anti-inflammatory m2 macrophages article download pdf full size image systemic t-cell response paraffin-embedded tissue samples triple-negative breast cancer pan-macrophage marker cd68 anti-inflammatory cd163 marker pan-macrophage marker frequently related subjects larger triple-negative/basal pro-inflammatory m1 macrophages microarray profile sets expression profiles--database full access medical research council umas research foundations gene expression levels privacy choices/manage cookies human breast cancer distinct immune functions cd208/dc-lamp staining absent/sparse macrophage infiltration cell rich areas author information authors human dendritic cells gene expression analysis anti-inflammatory environment [4] independent risk factor breast cancer specific anti-cancer therapy alternatively activated macrophages promoting tumor invasion monocyte/macrophage lineage anti-inflammatory subtypes specific phenotypic markers tumour-stroma ratio human colorectal cancer multivariate analyses revealed tumor-promoting capabilities monocyte/macrophage morphology including breast cancer gene expression data primary breast cancer mature m2 macrophages flow cytometric analyses

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
         description:Tumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also analyzed the prognostic value of the localization of CD163+ and CD68+ myeloid cells in human breast cancer. The extent of infiltrating CD163+ or CD68+ myeloid cells in tumor nest versus tumor stroma was evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s Rho and χ2 tests were used to examine the correlations between CD163+ or CD68+ myeloid cells and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the impact of CD163+ and CD68+ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free survival, breast cancer specific and overall survival. We found that infiltration of CD163+ and CD68+ macrophages into tumor stroma, but not into tumor nest, were of clinical relevance. CD163+ macrophages in tumor stroma positively correlated with higher grade, larger tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like breast cancer and inversely correlated with luminal A breast cancer. Some CD163+ areas lacked CD68 expression, suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact. CD68+ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast cancer specific survival. These findings highlight the importance of analyzing the localization rather than merely the presence of TAMs as a prognostic marker for breast cancer patients.
         datePublished:2012-07-23T00:00:00Z
         dateModified:2012-07-23T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-12-306
         keywords:
            Tumor associated macrophages
            Tumor stroma
            CD163
            CD68
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-306/MediaObjects/12885_2012_Article_3213_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-306/MediaObjects/12885_2012_Article_3213_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-306/MediaObjects/12885_2012_Article_3213_Fig4_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Catharina Medrek
               affiliation:
                     name:Skåne University Hospital, Lund University
                     address:
                        name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Fredrik Pontén
               affiliation:
                     name:Rudbeck Laboratory, Uppsala University
                     address:
                        name:Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karin Jirström
               affiliation:
                     name:Skåne University Hospital, Lund University
                     address:
                        name:Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karin Leandersson
               affiliation:
                     name:Skåne University Hospital, Lund University
                     address:
                        name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
      description:Tumor associated macrophages (TAMs) are alternatively activated macrophages that enhance tumor progression by promoting tumor cell invasion, migration and angiogenesis. TAMs have an anti-inflammatory function resembling M2 macrophages. CD163 is regarded as a highly specific monocyte/macrophage marker for M2 macrophages. In this study we evaluated the specificity of using the M2 macrophage marker CD163 as a TAM marker and compared its prognostic value with the more frequently used pan-macrophage marker CD68. We also analyzed the prognostic value of the localization of CD163+ and CD68+ myeloid cells in human breast cancer. The extent of infiltrating CD163+ or CD68+ myeloid cells in tumor nest versus tumor stroma was evaluated by immunohistochemistry in tissue microarrays with tumors from 144 breast cancer cases. Spearman’s Rho and χ2 tests were used to examine the correlations between CD163+ or CD68+ myeloid cells and clinicopathological parameters. Kaplan Meier analysis and Cox proportional hazards modeling were used to assess the impact of CD163+ and CD68+ myeloid cells in tumor stroma and tumor nest, respectively, on recurrence free survival, breast cancer specific and overall survival. We found that infiltration of CD163+ and CD68+ macrophages into tumor stroma, but not into tumor nest, were of clinical relevance. CD163+ macrophages in tumor stroma positively correlated with higher grade, larger tumor size, Ki67 positivity, estrogen receptor negativity, progesterone receptor negativity, triple-negative/basal-like breast cancer and inversely correlated with luminal A breast cancer. Some CD163+ areas lacked CD68 expression, suggesting that CD163 could be used as a general anti-inflammatory myeloid marker with prognostic impact. CD68+ macrophages in tumor stroma positively correlated to tumor size and inversely correlated to luminal A breast cancer. More importantly, CD68 in tumor stroma was an independent prognostic factor for reduced breast cancer specific survival. These findings highlight the importance of analyzing the localization rather than merely the presence of TAMs as a prognostic marker for breast cancer patients.
      datePublished:2012-07-23T00:00:00Z
      dateModified:2012-07-23T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-12-306
      keywords:
         Tumor associated macrophages
         Tumor stroma
         CD163
         CD68
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-306/MediaObjects/12885_2012_Article_3213_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-306/MediaObjects/12885_2012_Article_3213_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-12-306/MediaObjects/12885_2012_Article_3213_Fig4_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Catharina Medrek
            affiliation:
                  name:Skåne University Hospital, Lund University
                  address:
                     name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Fredrik Pontén
            affiliation:
                  name:Rudbeck Laboratory, Uppsala University
                  address:
                     name:Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karin Jirström
            affiliation:
                  name:Skåne University Hospital, Lund University
                  address:
                     name:Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karin Leandersson
            affiliation:
                  name:Skåne University Hospital, Lund University
                  address:
                     name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Skåne University Hospital, Lund University
      address:
         name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
         type:PostalAddress
      name:Rudbeck Laboratory, Uppsala University
      address:
         name:Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
         type:PostalAddress
      name:Skåne University Hospital, Lund University
      address:
         name:Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, Lund, Sweden
         type:PostalAddress
      name:Skåne University Hospital, Lund University
      address:
         name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Catharina Medrek
      affiliation:
            name:Skåne University Hospital, Lund University
            address:
               name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Fredrik Pontén
      affiliation:
            name:Rudbeck Laboratory, Uppsala University
            address:
               name:Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
               type:PostalAddress
            type:Organization
      name:Karin Jirström
      affiliation:
            name:Skåne University Hospital, Lund University
            address:
               name:Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Karin Leandersson
      affiliation:
            name:Skåne University Hospital, Lund University
            address:
               name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden
      name:Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
      name:Department of Clinical Sciences, Pathology, Skåne University Hospital, Lund University, Lund, Sweden
      name:Center for Molecular Pathology, Skåne University Hospital, Lund University, Malmö, Sweden

External Links {🔗}(128)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.41s.

LINK . SPRINGER . COM {}